Atai Life Sciences'' (NASDAQ: ATAI ) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC) approvals to begin participant enrollment in its Phase 1 trial of proprietary MDMA-based drug EMP-01 , designed to treat PTSD and other mental health conditions. The randomized, double-blind, placebo-controlled study intends to evaluate the safety and tolerability of single-ascending oral doses of EMP-01 in 32 healthy adult participants, as well as to assess the usability and acceptability of the IDEA-1 app in delivering “set and setting” content to participants in preparation for the drug administration. The research , of which results are expected by the second half of 2023, will include a range of behavioral assessments that, together with the pharmacokinetics and safety … Full story available on Benzinga.com
→ Google 번역
atai Life Sciences (ATAI) said on Tuesday its Phase 1 study to develop EMP-01 to treat post-traumatic stress disorder (PTSD) had received regulatory and ethics approvals from Medsafe…
→ Google 번역
- atai''s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a Phase 1 trial to assess th…
→ Google 번역
In last trading session, Atai Life Sciences N.V. (NASDAQ:ATAI) saw 0.8 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $3.22 trading at -$0.11 or -3.30% at ring of the bell on the day assigns it a market valuation of $558.83M. That closing price of ATAI’s stock … Atai Life Sciences N.V. (NASDAQ:ATAI) Shares Plunged -16.58% In A Week – But Can It Maintain Its Gains? Read More »
→ Google 번역
Atai Life Sciences N.V. (NASDAQ:ATAI) marked $3.44 per share on Wednesday, down from a previous closing price of $3.67. While Atai Life Sciences N.V. has underperformed by -6.27%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ATAI fell by -78.57%, with highs and lows ranging from […]
→ Google 번역
The season for psychedelics conferences is right around the corner. From very large and well-known events to small meets , this year’s remaining months are loaded with on-site and virtual discussions around the natural plant and synthetic medicines revolutionizing mental health. Let’s take a look at some of them taking place in the coming weeks. H.C. Wainwright 24th Annual Global Investment The H.C. Wainwright 24th Annual Global Investment Conference is set for September 12-14 . Both virtual and in-person at the Lotte New York Palace Hotel , the event invites public and private companies, industry and business development executives, institutional investors, private equity firms and venture capitalists to attend and profit networking opportunities, investor meetings and company presentations including big industry names like Braxia Scientific (OTC: BRAXF ) and A tai Life Sciences (NASDAQ: ATAI ). 12th Concordia Annual Summit Heads of state, leaders of the private and NGO sectors, and new and diversified perspectives will gather to explore tangible solutions to local and global challenges in the 12th Concordia Annual Summit on September 19-21 at the Sheraton New York Times Square Hotel.
→ Google 번역
The following slide deck was published by Atai Life Sciences N.V.
→ Google 번역
In the last trading session, 1.42 million Atai Life Sciences N.V. (NASDAQ:ATAI) shares changed hands as the company’s beta touched 0. With the company’s per share price at $4.21 changed hands at -$0.15 or -3.44% during last session, the market valuation stood at $685.98M. ATAI’s last price was a discount, traded about -325.18% off its … Atai Life Sciences N.V. (NASDAQ: ATAI): The Most Interesting Shares Today Read More »
→ Google 번역
NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor conferences in September:
→ Google 번역
Cathie Wood’s ARK Genomic Revolution EFT has been making big investments in the psychedelics sector since February 2022, most notably in Atai Life Sciences (NASDAQ: ATAI ) . The fund has now gone deeper and released an extensive report exploring “the therapeutic merits” and what the sector''s investment prospects look like. Written by research associate Pierce Jamieson , ARK’s “How ‘Far Out’ Are Psychedelic Therapeutics?” joins similar analyses by KPMG and Morgan Stanley . Together, they certainly weigh on what retail investors who are still unaware of the sector might consider a fairly good-looking market to get involved in. The piece walks the reader through a small intro on the history of psychedelic substances then moves to a scientific review of eight related compounds and their current clinical status. It then dives into which investments pose risks and which hold opportunities in the sector. The information published includes average trial costs, average time span for drug development …
→ Google 번역
Psychedelics biopharma company Lobe Sciences Ltd. (OTCQB: LOBEF ) signed a deal with Cantheon Capital, a development of cannabinoids and psychedelic drugs supporter, for aggregate proceeds to the company of up to $1.5 million for an annual term with a 15% interest. Funding for psychedelics research and clinical trials is certainly here to stay. In the last couple of weeks, other biotech companies advancing both classic and next-generation psychedelic medicines such as Bright Minds (NASDAQ: DRUG ), ATAI Life Sciences (NASDAQ: ATAI ) and Freedom Biosciences have also signed considerable loan agreements with major … Full story available on Benzinga.com
→ Google 번역
GAINERS: GH Research (NASDAQ: GHRS ) shares closed up 5.33% at $14.24 Compass Pathways (NASDAQ: CMPS ) shares closed up 3.47% at $17.57 ATAI Life Sciences (NASDAQ: ATAI ) shares closed up 2.31% at $4.42 Numinus Wellness (OTC: NUMIF ) … Full story available on Benzinga.com
→ Google 번역
Atai Life Sciences N.V. (NASDAQ:ATAI) price on Friday, August 19, fall -5.04% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $4.52. A look at the stock’s price movement, the close in the last trading session was $4.76, moving within a range at $4.47 and $4.8407. Turning to … Atai Life Sciences N.V. (ATAI): Is It Worth A Small Bite At $4.52? Read More »
→ Google 번역
atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, has announced that the company has entered into a term loan facility for up to $175 million with Hercules Capital, Inc. (NYSE: HTGC). Latham & Watkins LLP represents atai in the transaction with a team led […] The post Latham & Watkins Represents atai Life Sciences in Term Loan Facility for Up to $175 Million from Hercules Capital appeared first on Legal Desire .
→ Google 번역
Clinical-stage psychedelics company ATAI Life Sciences N.V. (NASDAQ: ATAI ) announced its financial results for the quarter ended June 30, 2022 and business updates, including a term loan facility agreement for up to $175 million provided by Hercules Capital Inc. (NYSE: HTGC ). The company expects the new non-dilutive financing facility, together with the total existing cash in hand, will provide cash runway until 2025 , as the flexible draw availability provides options to optimize liquidity and capital structure moving forward in ATAI’s developments. The Financial Results Total cash of $312.5 million for the period ended June 30, 2022, compared to $362.3 million as of December 31, 2021. The net decrease of almost $50 million was due to operating activities and additional investments in the platform companies, while receiving $1.9 million from the conversion of promissory notes and equity issuances. R&D expenses totaled $17.9 million and $33.4 million for the three and six months ended June 30, 2022 respectively, compared to $16.0 million and $21.6 million for the same periods in 2021.
→ Google 번역
https://www.investing.com/news/pro/atai-life-sciences-nv-pt-lowered-to-16-at-credit-suisse-432SI-2872916
→ Google 번역
Atai Life Sciences N.V. (NASDAQ:NASDAQ:ATAI) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Greg Weaver – Chief Financial Officer Stephen Bardin – Deputy…
→ Google 번역
ATAI Life Sciences (NASDAQ: ATAI ) reported its Q2 earnings results on Monday, August 15, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings ATAI Life Sciences missed estimated earnings by 4.35%, reporting … Full story available on Benzinga.com
→ Google 번역
atai Life Sciences (ATAI) entered into a term loan facility for up to $175M with Hercules Capital (HTGC)."While we continue to execute on our diversified pipeline of differentiated…
→ Google 번역
ATAI Life Sciences (NASDAQ: ATAI ) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here''s what investors need to know before the announcement. Analysts estimate that ATAI Life Sciences will report an earnings per share (EPS) of $-0.23. ATAI Life Sciences bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted … Full story available on Benzinga.com
→ Google 번역
NEW YORK and BERLIN, Aug. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its second quarter 2022 financial results and business update on Monday, August 15, 2022.
→ Google 번역
Atai Life Sciences N.V. (NASDAQ:ATAI) shares, rose in value on Friday, 07/15/22, with the stock price up by 2.41% to the previous day’s close as strong demand from buyers drove the stock to $4.25. Actively observing the price movement in the last trading, the stock closed the session at $4.15, falling within a range of … Is Atai Life Sciences N.V. (NASDAQ: ATAI) A Good Pick For New Investors Now? Read More »
→ Google 번역
Source: rhendrikdwenz via Shutterstock So far, 2022 has been a rocky year for Cathie Wood’s exchange-traded funds (ETFs). Her flagship fund, the ARK Innovation ETF (NYSEARCA: ARKK ) is down more than 50% year-to-date (YTD). Meanwhile, other Cathie Wood funds are posting similar returns. There may be light on the horizon, however. On June 27, ARKK received eight straight days of inflows totaling $639 million . In addition, the ETF manager remains highly convicted in her top positions , including Tesla (NASDAQ: TSLA ) and CRISPR Therapeutics (NASDAQ: CRSP ). Wood’s poor returns are partially due to the Federal Reserve lifting interest rates. Still, the investor believes that “deflationary forces” may cause the Fed to reverse on its plan to raise rates even higher. She notes that the dollar index has moved up by double digits this year, characterizing it as a “total anti-inflationary force.” Wood also says oil has declined by over 20% month-over-month and expects gold to “move below a two-year trading range.” This week was busy for Ark ETFs, which made several interesting purchases.
→ Google 번역
After a pause in the purchase of atai Life Sciences N.V. (NASDAQ:ATAI ) shares, Cathy Wood’s ARK Genomic Revolution ETF is back on the bid. The actively managed Fund that invests in early-stage emerging technology companies has increased its stake in atai to record amounts, presumably seeing value in the psychedelic biotech leader that’s been hit during the ongoing selloff in risk assets. According to updated ARK Genomic Revolution ETF holdings spreadsheet, the fund now owns 1,827,047 million shares—above the previous high of 1.689 million shares held in March, according to cathiesark.com. The aggregate jump in share ownership is the biggest increase since mid-March, when the ETF increased its stake by over 200,000 shares during the period March 11-14 period. Below, we … Full story available on Benzinga.com
→ Google 번역
GAINERS: Allied (OTC: ALID ) shares closed up 14.62% at $0.54 GH Research (NASDAQ: GHRS ) shares closed up 8.00% at $11.75 ATAI Life Sciences (NASDAQ: ATAI ) shares closed up 7.29% at $4.27 Compass Pathways (NASDAQ: CMPS ) shares closed up 6.55% at … Full story available on Benzinga.com
→ Google 번역
Atai Life Sciences N.V. (NASDAQ: ATAI ) recently filed a registration statement with the Securities and Exchange Commission for capital raise of up to $300 million through the issuance of common shares, debt securities, warrants and units. As explained by Jason Najum on Microdose , by using a shelf registration process the company can sell securities from time to time and in one or more offerings. A shelf offering permits the registration of a new batch of shares without having to sell the entire issue at once. And the capital raise may be held for over a three-year period, all of which gives the company the flexibility to act quickly if good opportunities arise. One of the best-capitalized companies … Full story available on Benzinga.com
→ Google 번역
Kures Therapeutics, an atai Life Sciences (ATAI) appoints of Chad E
→ Google 번역
GAINERS: Seelos Therapeutics (NASDAQ: SEEL ) shares closed up 6.77% at $0.69 Revive Therapeutics (OTC: RVVTF ) shares closed up 2.30% at $0.35 GH Research (NASDAQ: GHRS ) shares closed up 1.99% at $10.26 ATAI Life Sciences (NASDAQ: ATAI ) shares closed up 1.66% … Full story available on Benzinga.com
→ Google 번역
GAINERS: Seelos Therapeutics (NASDAQ: SEEL ) shares closed up 6.63% at $0.71 Compass Pathways (NASDAQ: CMPS ) shares closed up 4.90% at $10.70 ATAI Life Sciences (NASDAQ: ATAI ) shares closed up 4.29% at $3.65 GH Research (NASDAQ: GHRS ) shares closed up 2.47% … Full story available on Benzinga.com
→ Google 번역
GAINERS: ATAI Life Sciences (NASDAQ: ATAI ) shares closed up 4.17% at $3.50 Cybin (AMEX: CYBN ) shares closed up 1.07% at $0.56 LOSERS: Numinus Wellness (OTC: NUMIF ) shares closed down 8.65% at $0.20 Mind Medicine (NASDAQ: MNMD ) shares closed down 6.33% at … Full story available on Benzinga.com
→ Google 번역
ATAI Life Sciences N.V. (ATAI) shares closed today at 1.0% above its 52 week low of $5.90, giving the company a market cap of $997M. The stock is currently down 18.5% year-to-date, down 68.0% over the past 12 months, and down 68.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 30.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 6.8% lower than its 5-day moving average, 17.2% lower than its 20-day moving average, and 51.0% lower than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -19933.1% The company's stock price performance over the past 12 months lags the peer average by -164.8%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
→ Google 번역